Physician

Alam Leah Berke, MD

According to 2025 Medicare claims, Alam Berke, MD (NPI: 1518929140) practices dermatology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. Berke uses personal NPI as billing NPI and primary practice location at 33179-4840.

Berke's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 84 traditional Medicare patients, billed 513 HCPCS/CPT codes, and received $20,358 in Medicare payments. The top billing code was 11102 (Biopsy of related skin growth, first growth). Part D data shows 301 prescription claims across 118 beneficiaries totaling $49,801 in drug costs, led by Fluocinonide (Fluocinonide). Open Payments data shows 2 records totaling $47. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $34,739 to $20,358. Similarly, Part D prescription costs have fallen sharply in recent years, from $81,903 to $49,801. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$20K$40K2015 Medicare payment: $34,739 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $40,342 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $30,404 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $24,352 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $35,037 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $22,175 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $28,438 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $21,109 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $14,232 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $20,358 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151631,280$34,739
20161851,367$40,342
20171411,088$30,404
2018126893$24,352
20191441,167$35,037
2020102562$22,175
2021110617$28,438
202293461$21,109
202372336$14,232
202484513$20,358

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$183K$367K2015 Drug cost: $81,903 (USD; Tot_Drug_Cst)2016 Drug cost: $86,569 (USD; Tot_Drug_Cst)2017 Drug cost: $155,268 (USD; Tot_Drug_Cst)2018 Drug cost: $208,016 (USD; Tot_Drug_Cst)2019 Drug cost: $192,414 (USD; Tot_Drug_Cst)2020 Drug cost: $247,498 (USD; Tot_Drug_Cst)2021 Drug cost: $366,781 (USD; Tot_Drug_Cst)2022 Drug cost: $335,317 (USD; Tot_Drug_Cst)2023 Drug cost: $207,990 (USD; Tot_Drug_Cst)2024 Drug cost: $49,801 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015174496$81,903
2016206542$86,569
2017153405$155,268
2018195473$208,016
2019180485$192,414
2020117339$247,498
2021145435$366,781
2022114341$335,317
2023109296$207,990
2024118301$49,801

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
11102Biopsy of related skin growth, first growth1620$70
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more59113$66
99203New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more2222$65
17000Destruction of precancer skin growth, 1 growth2852$53
17003Destruction of precancer skin growth, 2-14 growths22265$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
FluocinonideFluocinonide531,348$1,923
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip26836$980
Triamcinolone AcetonideTriamcinolone Acetonide1003,031$911
Clobetasol PropionateClobetasol Propionate21570$659
Clindamycin PhosphateClindamycin Phosphate12345$247

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.2$47Verrica Pharmaceuticals Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Alam Leah Berke, MD?

Tedicare shows public-source Medicare data for Alam Leah Berke, MD (NPI 1518929140), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alam Leah Berke, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alam Leah Berke, MD?

A separate primary affiliated billing organization is not shown for this profile in the available data.

Does Alam Leah Berke, MD have Open Payments data?

Alam Leah Berke, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.